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Abstract The idea that individual tumors are antigeni-
cally unique has been around since the very dawn of our
recognition of adaptive immune response to tumors. That
idea has inspired a small number of attempts at individu-
alized immunotherapy of human cancers. Such previous
attempts for solid tumors have been hobbled by an inability
to define the individually unique antigenic repertoire of
tumors because of technological difficulties. The new
availability of rapid and cheap high throughput DNA
sequencing promises to overcome that hurdle. Using this
new ability, coupled with bio-informatic tools, it is now
possible to define the immunogenic repertoire of any tumor
to a high degree of granularity within a practical time
frame and an acceptable cost. The development of these
ideas, and a small number of such studies that underscore
this promise, is discussed. This new way—of characteriz-
ing the tumor immunome through characterization of the
tumor genome—has distinct challenges, including selec-
tion of the appropriate peptides, choosing methods of
immunizations that can incorporate tens of epitopes, and
addressing issues of antigenic heterogeneity of tumors.
However, tools for meeting these challenges exist and are
emergent.
Keywords Personalized medicine  Individualized
medicine  Bio-informatics  Immunomics  CIMT2012
Tumors as seen by T lymphocytes
T cells are the prime movers of the endogenous immune
response to cancer, although they may be aided (or hin-
dered) in this process by other cells. Although a number of
antibodies to molecules expressed on tumors (and normal
cells) are now used to treat cancers, they are used as
pharmacological rather than immunological agents. All the
immunological agents approved for treatment of human
cancers activate the T cell responses to cancers [1–3]. This
discussion will therefore focus purely on the T cell epitopes
of cancers and the responses elicited by them.
Much of our initial understanding about T cell epitopes
came from study of viral immunity. T cell epitopes of
viruses can be identified and can be used to elicit immune
responses and protective immunity against viruses. As it
became possible to generate T cells against mouse and
human tumors, it was expected that identification of epi-
topes of cancers could be similarly used to elicit immune
responses and protective immunity against cancers. It has
now been over 20 years since it became possible to identify
the T cell epitopes of mouse and human cancers of non-
viral origins [4], and a large number of T cell epitopes have
now been defined and characterized [5].
Such epitopes have fallen into two categories, one where
the epitopes seen by the antitumor T cells are identical
between normal and tumor cells, and second, where such
epitopes are specific to the tumor cells and not seen in
normal cells, by virtue of a tumor-associated mutation or
other genetic event. The former class of the T cell tumor
epitopes, the shared tumor epitopes, so-called because they
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are shared by tumors and by tumors and normal cells, has
generated much of the enthusiasm and activity over the last
20 years. To be clear, the shared epitopes themselves
consist of two sub-classes of epitopes—the differentiation
antigens (such as tyrosinase), which are shared between
normal tissues and tumors, and the ‘‘cancer testes’’ or CT
antigens (such as MAGE and NY-ESO1), which although
un-mutated are expressed on germinal tissues and cancers,
but not on normal adult tissues. It is important to point this
here because the CT antigens, although un-mutated, are
tumor specific (if one discounts the germinal tissues). The
shared epitopes have been tested extensively for their
ability to immunize and generate T cell responses and to
protect mice and men against cancers. Notwithstanding a
lone voice or two [6–8], the fact that these shared epitopes
are not tumor specific, and hence may not be immunogenic
or immune protective, has been mostly glossed over. (It is
useful to remember that the T cell epitopes of viruses were
of course all virus specific.) Indeed, the evidence from
mouse models lends credence to the idea that the lack of
tumor specificity of these epitopes is a barrier to their
ability to elicit immune-protective anti-tumor responses [9,
10]. Instead, the argument has been that since these epi-
topes are common between tumors and normal tissues, and
since there must exist a degree of tolerance to the antigens,
the goal should be to break tolerance against such self-
antigens. The possibility that such breaking of tolerance, if
achieved, would lead to unacceptable toxicities, has not
been generally considered to be a major problem. Since the
studies carried out thus far have failed to elicit potent
antitumor responses, or potent autoimmunity for that
matter, the issue of toxicities remains moot. However, two
large randomized multi-center clinical trials, actually the
largest ever trials in the history of cancer vaccination, are
currently testing whether immune response to one such
shared tumor antigen, MAGE, elicits clinical benefit in
cancer patients. The outcome of these trials will reveal if
immunization with the shared, non-tumor-specific epitopes
is tumor protective; if the answer is in the affirmative, the
results will also reveal, if such immunizations elicit path-
ological autoimmunity. Regardless of the outcome those
results shall be instructive.
The latter class of T cell epitopes, the ones where the
epitopes are tumor specific by virtue of the fact that a
mutation in a normal sequence has created a new epitope,
has been problematic as well: an overwhelming proportion
of these mutations is found in only a given tumor, that is,
the epitopes are individually distinct for a tumor. Although
immunization with such tumor specific epitopes in mouse
models of cancer has shown them to be highly tumor
protective for the tumor that harbor them [11–15]
(Table 1), and the indirect evidence in humans has been
tantalizing [16], what does one do with an individually
unique epitope even though it is tumor specific and perhaps
even immune protective against a tumor? How does one
generate a vaccine for just one tumor? The prospect of
generating T cells from individual patients, characterizing
the individually unique tumor-specific epitopes from these
T cells for each patient, and immunizing each patient with
such epitopes, is simply not practical for a variety of
obvious reasons. For these good reasons, this latter class of
epitopes has not elicited much enthusiasm.
To sum up the above, there are powerful scientific rea-
sons and data against the idea that the shared tumor anti-
gens may elicit protective tumor immunity; however, the
denouement for this line of thinking is not far off: the two
randomized trials with the shared MAGE antigen expect to
be un-blinded within the next two years. The idea that the
individually unique tumor antigens may be tumor protec-
tive is more appealing theoretically and is supported by
considerable mouse data and some human evidence;
however, it appears at first blush, to be logistically
Table 1 T-cell-defined epitopes of mouse tumors and their characteristics





IEk DFNHINVELSHLGK Unique Yes [11]
P68 helicase 8101 squamous
carcinoma
Kb SNFVFAGI Unique Yes [12]
P53 Meth A fibro-sarcoma Kd KYICNSSCM Unique Yes [13]
ERK2 CMS5 fibro-sarcoma LQIHSANVL Unique Yes [14]
L11 ribosomal
protein
Meth A fibro-sarcoma IEd EYELRKHNFSDTG Unique Yes [15]
P1A Many Ld LPYLGWLVF Shared Noa [9, 10]
AH1 Many Ld SPSYVYHQF Shared No [54], Un-published
The letter in italics denoted the altered residue created by a mis-sense mutation
a P1A has been shown to mediate tumor rejection if P1A and B7-1 expressing cells are used as vaccines [53]
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untenable. As a matter of fact, efforts to harness the indi-
viduality of immunogenicity of each cancer have a rather
long and interesting history. This is discussed in the next
section, followed by an overview of the extraordinary
opportunities now available for this pursuit because of the
availability of high throughput DNA sequencing
technologies.
Harnessing the individually distinct immunome of each
individual cancer: some ‘‘medieval’’ and ‘‘modern’’
history
The first hint that T cells may be recognizing individually
specific mutations in each individual cancer came long
before we knew of T cells. Prehn and Main [17], Klein
et al. [18] and others noted over 50 years ago that inbred
mice could be immunized against syngeneic tumors, even
autochthonous tumors, and that such immunity was indi-
vidually specific: tumors of the same histological type,
induced by the same carcinogen in mice of the same hap-
lotype, still showed individually distinct antigenicity. In a
dramatic demonstration, Globerson and Feldman [19]
showed that two tumors induced on each flank of a single
mouse by two independent injections of the same carcin-
ogen were individually distinct antigenically. Basombrio
[20] tested this individuality in a large panel of 25 tumors
and observed the ‘‘extreme rarity of either totally or par-
tially shared antigenic components between methylcho-
lanthrene-induced tumors, as demonstrated by rejection of
tumor cell inocula.’’
These observations starting well over 50 years ago
suggested that each time there was a new transforming
event, there was a new and unique pattern of immunoge-
nicity. One of the possibilities considered at the time was
that this uniqueness of immunogenicity was simply a
reflection of pre-existing unique patterns of immunoge-
nicity in the normal cells. Clever experiments, which tested
the patterns of immunogenicity of cells, transformed
in vitro with the same carcinogen soon suggested other-
wise: They showed that progeny of the same normal cell,
transformed in vitro, had unique patterns of immunoge-
nicity [21]. These ideas have simply stayed in the literature
for lack of avenues to explore them, until now, as discussed
in the next section.
And now for the ‘‘modern’’ history. A number of human
studies have attempted to harness the individually distinct
immunogenicity of individual human tumors. Three
examples will illustrate the point. B cell lymphomas
present a unique opportunity (no pun intended) because the
tumors each have a unique idiotype (antigen). Building on
the pioneering studies of Ronald Levy using anti-idiotypic
antibodies to treat B cell lymphomas [22], patients were
immunized with the idiotypes of their tumors and moni-
tored for disease free survival. Two randomized trials
failed to show statistically significant clinical benefit in the
idiotype-immunized arm [23, 24], while a third trial did
show such difference [25].
Among solid tumors, a series of randomized trials in
patients with colon cancers was performed where patients
were immunized post-surgical resection, with whole irra-
diated autologous tumor cells mixed with BCG, or were not
immunized. The last such randomized trial showed statis-
tically significant benefit in the immunized patients with
stage II, but not stage III colon cancer [26].
The heat shock protein (HSP)-based vaccine is yet
another way to harness the antigenic individuality of each
cancer. This approach is based on the demonstration that
molecules of HSPs of the hsp70 and hsp90 families are
associated non-covalently (1:1 or 2:1) with a broad array of
peptides generated in the cells during proteolytic degra-
dation [27]. These peptides consist overwhelmingly of self-
peptides, but also contain any non-self peptides generated
in the source from which the HSPs are isolated. Such non-
self peptides include viral peptides [28] (if HSPs were
isolated from virus-infected or transformed cells) or tumor
antigenic peptides if the HSPs were isolated from tumor
tissues [29, 30]. Thus, the purified HSP preparations are
actually HSP-peptide preparations. Upon immunization,
the HSP-peptide complexes are taken up by antigen pre-
senting cells of the host through HSP receptors [31, 32],
and the peptides are cross-presented by the MHC mole-
cules of the antigen presenting cells, which then engage the
T cells, and mediate anti-tumor responses. A Phase 3 trial
in patients with renal cell carcinoma in the adjuvant setting,
where each patient was immunized with HSP-peptide
complexes isolated from his/her own tumor, failed to show
statistically significant clinical activity in the overall pop-
ulation, although significant activity was observed in post
hoc sub-sets of early and intermediate stage disease [2]. A
large randomized trial using this approach is currently
underway in patients with glioblastoma multiforme.
There are two ways to look at this history of individually
specific vaccination against cancers. At first look, none of
these three approaches have succeeded: None is widely
used in cancer therapy today. The idiotype vaccine for B
cell lymphoma and the whole cell vaccine for colon cancer
showed statistically significant clinical activity, but are
encumbered by difficulties in vaccine production or regu-
latory concerns about vaccine quality. The HSP-based
vaccine failed to show statistically significant activity
except in post hoc sub-sets and, although approved for use
in Russia, has not been cleared for use in the US or Europe.
All three vaccines are under further improvement. How-
ever, if one looks at these three vaccines in the larger
universe of all cancer vaccines tested in Phase 3 trials, a
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somewhat different pattern emerges. With a single excep-
tion, all of the vaccines based on the idea of common
antigenicity of cancers have failed [1, 33], and the only one
that was approved for use in the US [3] is struggling to
achieve acceptance, partly because of lack of confidence in
its clinical activity. The results of ongoing randomized
clinical trials in patients with melanoma and lung cancer
vaccinated with the shared, un-mutated vaccine MAGE, as
also those of improved versions of the three autologous
vaccines discussed here, will bring some clarity to the
picture or may muddy it further. Regardless, scientific and
clinical data to date provide strong evidence for the exis-
tence of an individually distinct antigenic repertoire for
each individual cancer, and the feasibility of using this
repertoire for successful cancer therapy. This theme is
developed further in the next section.
Harnessing the individually distinct immunome of each
individual cancer: the genomic way
What is this antigenic repertoire that is individually distinct
for each cancer? What are its components? How is it gen-
erated? 20 years ago, I suggested that randomness of pas-
senger mutations in individual tumors generates this
repertoire [34]. The argument can be unfolded thus: because
the process of DNA replication is not completely accurate,
and each cell division in any cell leads to a small number of
errors, even after the repair mechanisms have corrected
most of the errors. This error rate can range anywhere
between one error in a billion to one error in a hundred
thousand base pairs replicated per cell division depending
upon the cell type and the degree of genomic instability in it
[35, 36]. Even at the lowest rate of errors, a tumor will
accumulate thousands of mutations by the time it progresses
from the first transformed cell to a clinically or radiologi-
cally detectable tumor. Simply by statistical probability, a
small proportion of these mutations will create new epitopes
for some of the MHC I alleles of the tumor. I had suggested
that (a) such neo-antigens will be created by the passenger
mutations that have nothing to do with the transformed
phenotype and that may or may not confer any survival
advantage to the tumor, and (b) since these are random
mutations, their repertoire for any particular tumor is likely
to be unique. This mechanism would explain the unique
antigenicity of tumors as observed by earlier workers as
discussed above. At the time this mechanism was predicted
(1993), high throughput DNA sequencing was still far
away, and the possibility that this hypothesis could be
experimentally tested did not really exist.
Fast forward to 2008, when high throughput DNA
sequencing technologies began to be usable. Using banked
samples of breast and colon cancers, and based on partial
sequences of tumor transcripts, Segal et al. [37] utilized the
algorithms for prediction of HLA binding sequences, and
in the first study of this kind, predicted individual breast
and colon cancers to have between 7 and 10 new and
tumor-specific HLA A201-restricted epitopes!
We made use of probability theory in estimating the
number of tumor-specific neo-epitopes in a tumor [38].
Some of the results were entirely expected, but provided
the benefit of quantitation, while others were novel. Among
the expected results, the analysis showed that the number
of potential neo-epitopes (a) varies directly as a function of
the mutation rate and (b) increases exponentially with
increasing number of cell divisions (i.e., the older a tumor,
the more neo-epitopes it has). Further, as expected, it
showed that the tumors become more antigenically heter-
ogeneous as they grow. In a novel deduction, the analysis
showed that the death rate within a tumor has a profound
effect on its immunogenicity. A tumor with a higher death
rate will require many more cell divisions to achieve a
certain mass as compared to a tumor with a lower death
rate. Therefore, a tumor with a higher intrinsic death rate
will be more immunogenic. This result places tumor
immunogenicity at the intersection of a number of non-
immunological characteristics such as tumor vasculariza-
tion, hypoxia, size and remains to be fully understood or
exploited.
Predictions and theoretical considerations aside, the first
actual effort at genomics-guided definition of tumor-spe-
cific epitopes was published by Sahin and colleagues [39].
Using exome sequencing of a cell line derived from the
spontaneous mouse melanoma B16, Castle et al. uncovered
tens of neo-epitopes generated by mis-sense mutations and
characterized them with respect to their immunogenicity;
they observed that a significant proportion of the predicted
neo-epitopes was actually immunogenic in vivo. They also
showed that immunization with two of such neo-epitopes
modulated the course of tumor growth in tumor-bearing
and prophylactically treated animals. These findings,
important in and of themselves, were particularly inter-
esting because they were made in a poorly immunogenic
tumor line.
Schreiber and colleagues used high throughput DNA
sequencing to build on their work on immunoediting of
cancers [40]; they identified a mutation-generated epitope
in a tumor arising in an immunodeficient mouse, and
showed that this neo-epitope becomes a tumor-rejection
antigen upon transplantation into an immunocompetent
mouse, and becomes the subject of immunoediting.
Our laboratory has carried out genomics-guided identi-
fication of several chemically induced and spontaneous
mouse tumors [41]. Using methods broadly similar to those
of Castle et al. [39], but with significant differences, these
studies have un-covered hundreds of epitopes in the
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chemically induced tumors and a much smaller number in
the spontaneous tumors and have shown a proportion of
them to be immunogenic in vivo.
Collectively, the genomics-driven approach to identifi-
cation of tumor-specific neo-epitopes has just begun and is
beginning to support the postulate [34] that (a) tumors do
harbor an individually distinct repertoire and (b) that this
repertoire is created by randomness of passenger muta-
tions. While the previous approaches to harnessing this
individually specific repertoire [26, 34] were handicapped
by the inability to actually identify this repertoire for
individual tumors, the new genomics technologies promise
to help overcome that critical hurdle.
Challenges in translation to the human setting
The genomics-driven approach to harnessing the individ-
ually distinct repertoire of tumor-specific mutations
requires significant enquiry and resolution in mouse mod-
els; regardless, it may not be entirely out of place to begin
to consider the challenges in translating this approach to
the human situation. Rapid and cheap high throughput
sequencing of exomes or transcriptomes is not a challenge
anymore and most core facilities at academic institutions as
well as commercial facilities do this readily. Bio-infor-
matic analysis of such sequences is also becoming more
widely accessible through pipelines already generated.
However, a number of key challenges remain.
Selection of candidates of immunization
It is clear that a pipeline of potentially immunogenic epi-
topes can be generated through analyses in silico [42, 43].
The challenge is to trim this (expected-to-be-quite-long)
list into a list that is small enough to be practical and
contains epitopes that will be truly tumor protective. (See
also the issue of antigenic heterogeneity below.) Not all
immunogenic epitopes will be tumor protective, and we
cannot reasonably immunize patients with all the putative
epitopes identified in silico. A better understanding of this
question is perhaps the single most significant challenge in
translating genomics into true tumor immunomics.
Another issue greatly worthy of consideration is the
possibility that immunization with a mutated epitope may
elicit cross-reactive T cell response against the wild-type
epitope as well. This raises the specter of at least some
degree of autoimmunity, which may or may not be patho-
logical. One may draw some lesson from the fact that
immunizations of patients with un-mutated self-epitopes
have seldom elicited pathological autoimmunity [1, 3].
Regardless, there is need for caution in this regard, and only
further studies in mice and humans shall clarify this issue.
Technology of immunization
How do we immunize? Do we use a collection of GMP-
grade peptides or do we use RNA encoding multiple epi-
topes [44, 45]? What adjuvants do we use? How much
immunogen should be used? What should be the regimen
of immunization? These questions do not require a con-
ceptual leap, but they do need considerable examination
and experimentation.
Antigenic heterogeneity
This issue is a large one, but arguably less significant than
it may appear. The idea that tumor-specific neo-epitopes
are generated by random mutations inherently harbors the
idea of extensive antigenic heterogeneity: The mutations
that occurred earlier in the clonal expansion of a tumor are
likely to be imprinted on a larger proportion of tumor cells
than those that occur later, assuming that both classes of
mutations are neutral with respect to any survival advan-
tage or disadvantage on cells. This scenario creates an
image of a highly compartmentalized tumor-cell popula-
tion, which contains a large number of epitopes presented
by narrower and narrower segments of the tumor (Fig. 1).
The reality is actually likely to be different from that
Fig. 1 Antigenic heterogeneity in tumor masses. A schematic
showing the emergence of random passenger mutations (that are
not required for the transformed phenotype and that do not confer any
survival advantage or disadvantage and assuming zero tumor cell
death) in a growing tumor mass. The mutation that occurs at the first
division of the transformed cell is imprinted on 50 % of the
population, while mutations occurring in subsequent cell cycles
(red, green, purple, turquoise, and orange, in that order) are presented
on increasingly narrower population segments, leading to a tumor
with various sub-population of cells expressing different sets of
mutations. The figure may appear to suggest (incorrectly) that tumors
are actually compartmentalized in this manner: Since newer muta-
tions are as likely to occur in cells that harbor older mutations as in
the cells that do not, the tumor mass will actually be a chimera of cells
presenting large numbers of overlapping sets of neo-epitopes
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caricaturized in Fig. 1. The new mutations are as likely to
occur in cells that harbor the older mutations as in cells that
do not (see [46–49] for stimulating discussion). The net
result would be not a compartmentalized population of
tumor cells as in Fig. 1, but a tumor mass that is a hope-
lessly mixed chimera of cells that each contain different
sets of overlapping epitopes. The challenge would be to
immunize with a large enough cocktail of overlapping
epitopes. It should be possible to identify this cocktail for
any given tumor (and its metastatic progeny) by the use of
a suitable combination of sequencing and bio-informatic
methods. This is important work that needs to be done, but
can be done. Finally in this regard, it is worth remembering
that one does not need to eliminate 100 % of the cells to
obtain significant clinical benefit; bystander killing of
antigen-negative tumor cells is a robust reality [50, 51].
Regulatory challenges
There are obvious regulatory challenges in the use of an
individual-specific platform of immunotherapy. The rea-
sonable requirements of quality controls for each lot of
drug are far more complex in an individualized therapy
(where the drug made for each individual patient is a new
drug lot) than in a traditional therapy where a single lot
caters to a large patient population. However, many if not
most of these regulatory challenges have already been
addressed to a significant degree since a large number of
clinical trials (including randomized multi-center Phase 3
clinical trials) have been conducted previously with indi-
vidual-specific immunotherapies [2, 26].
Meeting these challenges is our immediate task. To
quote the 16th President of the United States, ‘‘As our case
is new, so we must think anew, and act anew.’’ [52].
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